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A b s t r a c t - - T h e  metabolism of  9-fl-D-arabinofuranosyladenine (ara-A, vidarabine) and its effects on 
DNA synthesis were compared in uninfected and herpes simplex virus type-1 (HSV-1)-infected KB 
cells. In the absence of an inhibitor of adenosine deaminase, ara-A was deaminated to 9-fl-o- 
arabinofuranosylhypoxanthine and phosphorylated to ara-A-5'-mono-, di- and triphosphates in both 
types of ceils. When an inhibitor of adenosine deaminase (coformycin) was added to cell cultures, 
nucleotides were the only metabolites detected--primarily the 5'-triphosphate of ara-A (aATP). Detailed 
studies performed in the presence of coformycin established that the net rate and extent of aATP 
formation were the same in uninfected and HSV-l-infected cells. After a 12-hr exposure to 50 ~M 
ara-A, intracellular concentrations of aATP were approximately 40/zM. Levels of aATP correlated 
directly with inhibition of total DNA synthesis. Approximately 0.7/zM aATP was required for 50% 
inhibition of total DNA synthesis in both uninfected and HSV-l-infected cells. Following removal of 
ara-A-containing culture medium, aATP levels in uninfected cells declined with a half-life of 3.2 hr. In 
marked contrast, the half-life in HSV-l-infected cells was 9.3 hr; this may explain why as little as a 3- 
hr exposure to ara-A resulted in a significant HSV-1 titer reduction. Taken together, the data show that 
when ara-A was removed from culture medium, levels of aATP persisted longer in HSV-l-infected cells 
thereby prolonging antiviral activity. This effect could be important in vivo where levels of ara-A 
oscillate with dosing schedule. 
Vidarabine (ara-A)~ is a clinically useful antiviral 
drug active against a broad spectrum of DNA viruses 
including HSV-1 [1-3]. It is effective in the therapy 
of several diseases caused by human herpes viruses 
including herpes keratitis, herpes encephalitis and 
varicella zoster in immunosuppressed patients [3, 4]. 
The clinical efficacy of ara-A most likely is based 
upon its capacity to inhibit virus replication at con- 
centrations which do not produce overt cytotoxicity 
in uninfected cells [5, 6]. We have found that this 
selectivity is related directly to a preferential inhibi- 
tion of viral D N A  synthesis compared to cellular 
DNA synthesis [7, 8]. 
Although a number of possibilities have been 
explored [6, 9-11], the biochemical basis for inhi- 
bition or alteration of D N A  synthesis by ara-A 
involves the following mechanisms: (1) inhibition of 
viral and, to a lesser extent, cellular DNA poly- 
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merases by aATP [12-14], (2) inhibition of 
ribonucleoside diphosphate reductase by aATP§, a 
mechanism which would potentiate the inhibition of 
D N A  polymerase [15], (3) incorporation of aAMP 
residues into D N A  [16] which retard the rate of chain 
elongation [17], and (4) inhibition of S-adenosyl-L- 
homocysteine hydrolase [18] with subsequent 
reduction of methylation reactions resulting in cyto- 
toxicity [19]. 
All  of these mechanisms except (4) require the 
bioconversion of ara-A to aATP. Several groups 
have examined the phosphorylation of ara-A in unin- 
fected mammalian cells [20-23], but none have exam- 
ined aATP formation in herpesvirus-infected cells. 
Furthermore,  the preferential metabolism of ara-A 
by HSV-induced enzymes would provide a mech- 
anism for achieving selective antiviral activity similar 
to that observed with a number of pyrimidine anti- 
metabolites [11,24,25]. Therefore, we have ex- 
plored this possibility by studying the deamination 
and phosphorylation of ara-A in the presence and 
absence of an adenosine deaminase inhibitor 
(coformycin [26]) in both HSV-l-infected and unin- 
fected cultures of KB cells. In conjunction with this 
study, the relationship of ara-A metabolism to the 
degree of inhibition of D N A  synthesis and HSV-1 
replication also was investigated. 
MATERIALS AND METHODS 
Chemicals. Ara-A was provided through the cour- 
tesy of Dr. H. E. Machamer,  Parke, Davis & Co.,  
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Detroit,  MI. aAMP and aHMP were gifts of Dr. R. 
L. Tolman, ICN Nucleic Acid Research Institute, 
Irvine, CA. aADP and aATP were purchased from 
Terra-Marine Bioresearch~ La Jolla, CA. All other 
purine bases, nucleosides and nucleotides used as 
standards were obtained from Sigma Chemical Co., 
St. Louis, MO, or from P-L Biochemicals, Inc., 
Milwaukee, WI. [2-3H]Ara-A (10-15 Ci/mmole) and 
[8-14C]adenine (56 mC~/mmole) were obtained from 
New England Nuclear, Boston, MA. [methyl-3H] - 
Thymidine (7 and 45Ci/mmole) and [2-14C] - 
thymidine (56mCi/mmole) were purchased from 
Nuclear Dynamics, Inc., El Monte, CA. Coformycin 
was a gift of Prof. H. Umezawa, Institute of 
Microbial Chemistry, Tokyo, Japan. 
Cell culture techniques and virus propagation. KB 
cells, an established human cell line derived from an 
epidermoid carcinoma of the mouth, and the HF 
strain of HSV-1 were the gift of Dr. G. H. Cohen, 
University of Pennsylvania, Philadelphia, PA. The 
routine growth and passage of KB cells and BHK 
21/4 cells, techniques used for the enumetation of 
cells, and the determination of cell viability have 
been described previously [7, 8]. Monolayer or spin- 
ner (suspension) cultures of KB cells were main- 
tained in medium supplemented with 10% exten- 
sively heat-inactivated calf serum in order to 
eliminate serum-associated adenosine deaminase 
[27]. The concentration of arginine in medium used 
with HSV-l-infected cells was doubled to 1.2 mM to 
support virus replication [28]. The propagation and 
titration of HSV, protocols for measuring DNA syn- 
thesis, and the separation of viral and cellular DNA 
in HSV-l-infected cells also have been described 
previously [7,8]. All cell lines were screened 
periodically by Microbiological Associates, 
Bethesda, MD, and found to be free of mycoplasma. 
Due to the known effects of ara-A on cell volume 
[29], the volume of KB cells growing in spinner 
cultures was determined. Wet mounts of cells and a 
calibrated micrometer were photographed through 
a Zeiss Photomicroscope II with transmitted light 
interference optics. Cell diameters were measured 
on whole field prints using a hand comparator fitted 
with a linear mm scale reticule. Cell diameters were 
converted to volume assuming spherical geometry. 
Measurements were made at 6, 12 and 24 hr after 
seeding uninfected of HSV-l-infected spinner cul- 
tures containing 0, 0.5, 10, or 50#M ara-A plus 
3.5 #M coformycin. Measurements also were made 
with 10~M ara-A in the absence of coformycin. 
Several fields of cells were used for each set of 
conditions so that >125 cells per flask per time point 
were measured. Measurements from at least dupli- 
cate flasks were used in all determinations. Cell 
Chex (stabilized L cells, Streck Laboratories) with a 
volume of 2100 -+ 15 um 3 were included as a ref- 
erence standard. The volume of uninfected KB cells 
in the absence of drug was 3083 +- 971 #m 3 in twenty- 
one separate determinations. Volume increases of 
12, 27 and 42%, respectively, were noted after 12 hr 
in the presence of 0.5, 10 and 50 #M ara-A plus 
3.5/LM coformycin. Volumes of HSV- 1-infected cells 
increased markedly with time in the absence of 
ara-A but were similar to the above values in the 
presence of the drug. 
Ara-A metabolism studies. Tritiated ara-A 
obtained for these studies contained 1.0 to 1.3% 
[3H]adenine (determined by silica gel TLC [311]). 
resulting in approximately 0.5 ng/ml in medium con- 
taining 2 #Ci/ml [3H]ara-A. The [3H]adenine was 
removed by incubating medium containing [3H]ara- 
A (10-15 Ci/mmole), 3.5 uM coformycin, 1.2 mM 
arginine and 10% heat-inactivated calf serum with a 
suspension of KB cells (about 300 × 103 cells/ml). To 
monitor the duration of incubation needed to remove 
[3H]adenine, [14C]adenine was added to give 2.5 ng/ 
ml, resulting in approximately 1000cpm [~4C]- 
adenine/ml of medium. When radioactivity from 
[~4C]adenine was no longer detectable, it was assum- 
ed that the contaminating [3H]adenine was removed 
from the medium as well. The entire suspension 
culture was centrifuged and the supernatant medium 
used in subsequent metabolism experiments with 
fresh cells. During a 30-min incubation, greater than 
90% of adenine-associated radioactivity was re- 
moved from the medium but no more than 5% of 
[3H]-ara-A was lost during this preliminary 
incubation. 
For studies on ara-A metabolism and DNA syn- 
thesis, a sterile stock solution of unlabeled ara-A 
plus 3.5 #M coformycin was added to the [3H]ara-A- 
containing preincubated medium to give the desired 
final drug concentration. Cells that previously had 
been virus or mock infected were added to the drug- 
containing medium and were maintained at 37 ° in 
spinner flasks. At  selected times after initiation of 
the spinner cultures, separate aliquots of cells were 
removed for determination of cell viability, cell num- 
ber (see above), DNA synthesis rates, and virus 
titers (described below), and for chromatographic 
determination of arabinosyl nucleotides. 
Chromatographic assays were performed by 
removing 5-ml aliquots of cell suspension and 
centrifuging at 600 g for 10 min at 4 °. The supernatant 
fraction was carefully and entirely aspirated. The 
pellet was kept on ice and 0.1 ml of ice-cold 70% 
ethanol was added. After  vortexing, the samples 
were stored at - 2 0  ° at least overnight. This pro- 
cedure disrupted cell membranes as observed with 
the Zeiss photomicroscope. Soluble nucleotides did 
not increase if ethanol extracts were sonicated for 
60 sec at 20 kHz in a Bronwill sonicator (Bronwill 
Scientific, Rochester, NY) set to deliver 70 W of 
accoustical power through a needle probe. After 
removal of cells, aliquots of culture medium also 
were brought to a final concentration of 70% ethanol 
and were stored at - 2 0  ° . Following storage, all 
samples were centrifuged to pellet precipitated mat- 
erials before chromatographic assay. 
Chromatographic identification o f  ara-A metab- 
olites. Nucleosides and bases were identified by TLC 
on silica gel plates (Analtech, Newark, DE) as 
described previously [30]. Stock solutions of ara-A, 
ara-H, adenine and hypoxanthine were spotted on 
TLC plates along with 5- to 10-~1 aliquots of ethanol- 
containing supernatant fractions from cells or culture 
medium. Following chromatography in the lower 
phase of chloroform-methanol-15% ammonia 
(3 :2:1 ,  by vol.), compounds were identified as de- 
tailed elsewhere [31] by fluorescence quenching and 
amount of label present in eluted fractions. Coinci- 
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dence of radioactivity with reference compounds was 
taken as indicating identity of labeled and reference 
compounds. 
Nucleotides were identified in a like manner by 
TLC on PEI-cellulose sheets (Brinkmann Instru- 
ments, Des Plains, IL). Stock aqueous solutions of 
AMP, dAMP, aAMP, ADP, dADP, aADP, ATP, 
dATP, aATP, IMP, dlMP, aHMP, IDP, dlDP, ITP, 
dlTP were spotted along with 5- to 50-~1 aliquots 
of ethanol-containing cell extracts. Two-dimensional 
chromatography was performed exactly as detailed 
earlier [32] and gave base line resolution of all 
nucleotides. Sections of the plastic-backed PEI plates 
were cut, placed into counting vials, and extracted 
with 2.0ml of 0.1 N HC1 in methanol for 15 hr at 
37 ° . Scintillation solution was added, samples were 
counted, and disintegrations per minute for each 
fraction were determined. Concentrations of 
arabinosyl nucleotides were calculated based upon 
the known specific activity of ara-A. The con- 
centration of aATP in pmoles/106 cells was converted 
to/~moles/liter based upon the volume of KB cells 
presented above. The rate of aATP disappearance 
following removal of ara-A from culture medium 
was determined by linearly regressing the log of 
aATP concentration against time. Data points from 
four separate experiments with uninfected cells fit 
the individual regression lines with r 2 values > 0.91. 
Values for experiments with HSV-l-infected cells 
were 0.69 for drug removal at 3 hr and 0.85 and 0.98 
for drug removal at 6 hr. 
Determination of virus titer and rates of DNA 
synthesis. These two variables were determined in 
the same cultures used for studying ara-A metab- 
olism. During incubation of cells with [3H]ara-A in 
spinner cultures, two additional 5- or 6-ml aliquots 
of cell suspension were removed. (Virus- and mock- 
infected cultures without ara-A also were included 
in all these experiments.) One set of aliquots was 
frozen at - 70  ° for subsequent determination of virus 
titer as mentioned above. The other set of aliquots 
was placed in glass tubes containing 0.1 ml of labeled 
thymidine to give a final concentration of 0.5/~Ci/ml 
[14C]thymidine or 2.0/~Ci/ml [3H]thymidine. Con- 
current studies published earlier [31] established that 
the effect of ara-A (plus coformycin) on DNA syn- 
thesis could be measured accurately by labeled 
thymidine incorporation at ara-A concentrations 
< 50 #M. 
Immediately after cells were mixed with isotope, 
100/A of the suspension was spotted in triplicate on 
filter paper circles for determination of background 
radioactivity. Tubes then were incubated in a 37 ° 
water bath shaking at 200 excursions/min. After 0.5 
or 1 hr, 100/~1 of each suspension was spotted in 
triplicate on filter paper circles and processed as 
described [7, 8]. Samples of [3H]ara-A-treated cells 
also were spotted on filter papers before and after 
the thymidine pulse exposure. Data were tabulated 
as radioactive thymidine incorporated into acid 
insoluble material per 10 3 cells, and inhibition of 
DNA synthesis in drug-treated cultures was deter- 
mined as a percent of that in cultures without drug. 
Data analyses. Concentrations of aATP in un- 
infected and HSV-l-infected cells were compared 
using Student's t-test [33, 34]. Dose-response 
relationships were constructed by linearly regressing 
probit values of the percent inhibition of DNA syn- 
thesis or HSV-1 titer reduction against log drug 
concentrations. IC50 concentrations and the 95 % con- 
fidence intervals were calculated from the regression 
lines using the methods described by Goldstein [33]. 
Identity of any two dose-response curves was tested 
by calculating P values for the equality of the 
regressions and slopes [5, 34]. 
RESULTS 
Metabolism of araoA in the presence and absence 
of coformycin. Preliminary experiments were per- 
formed to examine the metabolism of ara-A in mock- 
infected and HSV-l-infected cultures of KB cells. 
Following a 1-hr incubation of monolayer cultures 
with or without coformycin and selected con- 
centrations of [3H]ara-A, labeled nucleosides and 
nucleotides were characterized chromatographically. 
Chromatography of extracts from culture media and 
cells exposed to ara-A .plus 3.5/~M coformycin 
revealed the presence of [~H]ara-A alone in culture 
media and [3H]ara-A plus 3H-labeled nucleotides in 
cells. In media and cells grown in the absence of 
coformycin, [3H]ara-H was the only additional com- 
pound detected accounting for 45 % of the label. This 
metabolism was caused by cellular deamination of 
ara-A since serum adenosine deaminase was inac- 
tivated by heating [27]. [3H]aATP was identified by 
chromatography of nucleotides in cell extracts. The 
amount of aATP formed increased with increasing 
concentrations of ara-A and the presence of 
coformycin but otherwise did not vary greatly 
whether or not cells were infected with HSV-1. For 
example, when monolayer cultures were incubated 
with 0.2, 10 or 50/~M ara-A plus coformycin, 0.24, 
8.7 and 30.3pmoles aATP/106 cells, respectively, 
were formed in mock-infected cells compared to 
0.21, 11.3 and 30.7pmoles/106 cells in HSV-1- 
infected cells. [3H]ATP also was formed in all cul- 
tures and was approximately 2.5 times the amount 
of [3H]aATP. We do not, however, attribute the 
formation of [3H]-ATP to the metabolism of [3H]- 
ara-A. Rather [3H]-ATP appeared to be formed 
as a consequence of the metabolic salvage of [3H]- 
adenine found as a 1.3% contaminant in the prep- 
aration of [3H]ara-A. In subsequent experiments 
(described below) where the contaminating [3HI- 
adenine was reduced to <0.1% of [3H]ara-A (see 
Materials and Methods), the amount of [3H]ATP 
never was more than 10% of the amount of [3H]- 
aATP. No additional labeled nucleotides were 
detected in the cell extracts other than small amounts 
(<10% of the corresponding triphosphates) of 
aADP, aAMP, ADP, and AMP. 
Phosphorylation of ara-A in mock-infected and 
HSV-l-infected KB cells. More extensive studies on 
the metabolism of ara-A were performed using sus- 
pension (spinner) cultures of KB cells. In this and 
all subsequent experiments, coformycin was added 
to totally inhibit the deamination of ara-A. After 
virus or mock infection, cells were resuspended in 
medium containing 10/~M [3H]ara-A, and samples 
of the cell suspensions were removed at selected 
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Fig. 1. Metabolism of ara-A by uninfected and HSV-l-infected KB cells. Spinner cultures of mock- 
infected (dashed lines, open symbols) and HSV-l-infected (solid lines, closed symbols) KB cells were 
suspended in culture medium containing 10/~M [3H]ara-A (2 #Ci/ml) plus 3.5/aM coformycin and were 
incubated at 37 °. At the times indicated, 5-ml aliquots of cells were removed and centrifuged, medium 
was aspirated, and cells were extracted with 70% ethanol. Labeled nucleotides were identified by two 
dimensional TLC. Key: aATP (A,  &), aADP ([~, I ) ,  and aAMP (O, O). 
times for chromatographic identification of labeled 
intracellular nucleotides. Tritiated aATP was the 
major metabolic product accounting for >90% of 
the labeled nucleotides. Less than 10% of the label 
was associated with aAMP and aADP. Little or 
no label chromatographed with any other ribosyl, 
deoxyribosyl, or arabinosyl nucleoside-5'-mono-, 
di-, or triphosphate of adenine, hypoxanthine or 
guanine. Intracellular concentrations of aATP 
increased during the 12-hr incubation period in both 
uninfected and HSV-l-infected cells (Fig. 1). Con- 
centrations shown in Fig. 1 were converted to 
/~moles/liter based on cell volumes determined as 
described in Materials and Methods. At 1 hr, con- 
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Fig. 2. Phosphorylation of ara-A plus inhibition of DNA synthesis and viral replication. Spinner cultures 
of mock-infected (open symbols) and HSV-l-infected (closed symbols) KB cells were incubated with 
1/~M [3H]ara-A (2 #Ci/ml) plus 3.5/~M coformycin for 12 hr at 37 °. Intracellular concentrations of aATP 
(A,  A), incorporation of [3H]dThd into acid-precipitable material (0,  II), and virus titers (open and 
hatched histograms respectively) were determined in the absence and presence of drug at all indicated 
times. In the absence of drug, an average of 1268 and 1570 cpm, respectively, were incorporated per 
100 #1 of suspensions of mock-infected and HSV-l-infected cells during 0.5 hr exposures to 2 ~Ci/ml 
[3H]dThd. Common lines have been drawn through data from both mock-infected and HSV-l-infected 
cultures because of the similarity of measured values. Data at 12 hr also are included in the dose- 
response curves presented in Fig. 3. 
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Fig. 3. Dose-response relationships between ara-A concentrations in culture media and aATP formation, 
inhibition of DNA synthesis, and HSV-1 titer reduction. Spinner cultures of mock-infected (open 
symbols) and HSV-l-infected (closed symbols) KB ceils were incubated for 12 hr with 0, 1, 10 or 
50/JaM [SH]ara-A plus 3.5/AVl coformycin. Intracellular concentrations of aATP (A, &), [3H]dThd 
incorporation into acid precipitable material ([2, II), and virus titer (O) were determined. Data obtained 
only at 12 hr are presented. 
centrations were 5.0 and 4.5 #M, respectively, ip 
uninfected and HSV-l-infected cells, increasing to 
20 and 26/aM, respectively, at 12 hr. 
The rate of aATP synthesis during the initial hour 
of incubation was virtually identical in uninfected 
and HSV-l-infected cells (Fig. 1). The slightly 
greater amounts of aATP observed at later times in 
HSV-l-infected cells were not seen in subsequent 
experiments (Figs. 2--4). A comparison of data 
obtained in all experiments (Figs. 1--4 plus text) 
established that there were no differences in the 
amounts of aATP present in uninfected and HSV-1- 
infected cells. After 1 hr of incubation, the aATP 
concentration in uninfected cells was 
1.08 --- 0.35 pmoles/106 cells (mean -+ S.D. normal- 
ized per ~tmole ara-A/L culture medium) compared 
to 0.94 + 0.30 pmole/106 HSV-l-infected cells (P = 
0.25, N = 14 observations each). At 10-12 hr, the 
amounts of aATP present in uninfected and infected 
cells were 3.7 --. 2.3 and 5.3 -+- 3.4pmoles/106 cells 
respectively (P = 0.40, N = 5 and 7 observations 
respectively). 
Correlation of aA TP formation with inhibition of 
DNA synthesis and virus replication. Ara-A phos- 
phorylation was compared to inhibition of DNA 
synthesis using spinner cultures of mock-infected 
and HSV-l-infected KB cells. In this way aATP 
formation, DNA synthesis, and HSV-1 titers could 
be examined as functions of virus infection, drug 
concentration, and time. In one such experiment, 
mock-infected and HSV-l-infected cells were incu- 
bated for 12 hr in the presence of 0, 1, 10, or 50 pM 
ara-A (Figs. 2 and 3). Figure 2 presents the effects 
of 1/~M ara-A different times. The intracellular 
levels of aATP increased at the same rate in mock- 
infected and HSV-l-infected cells. At the same time, 
DNA synthesis and HSV-1 titers fell in the presence 
of ara-A. At 10 and 50 #M ara-A, similar temporal 
relationships were observed but levels of aATP were 
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Fig. 4. Retention of intraceilular aATP by uninfected and 
HSV-l-infected cells. Spinner cultures of cells were incu- 
bated at 37 ° without and with 10 ~ [3Hlara-A (2/tCi/ml) 
plus 3.5/zM coformycin. At 3 or 6 hr, each culture was 
divided into two portions, and the cells in one portion 
were removed from the original medium by two cycles 
of centrifugation and resuspension in drug-free medium. 
Incubation of drug-containing and drug-free cultures was 
continued. Concentrations of aATP and virus titers were 
determined using aliquots of cells removed at the times 
indicated, aATP concentrations are presented for mock- 
infected (©) and HSV-l-infected (O) ceils incubated 
without removal from ara-A-containing medium and for 
uninfected (D) and HSV-l-infected ceils removed from 
drug at 3(x) or 6 (11) hr. Data from four experiments with 
uninfected cells and two with infected cells were combined 
to generate the regression lines which begin at 6 hr. 
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Fig. 5. Effect of drug removal on titers of HSV-1. Virus 
titers were measured in the experiment involving drug 
removal at 3 hr described in the legend to Fig. 4. Titers are 
given for cells incubated in the following ways: (1) in the 
absence of drug (O), (2) in the absence of drug but sub- 
jected to the wash procedure (O), (3) in the presence of 
10/~M ara-A (11), and (4) washed free of drug at 3 hr (r~). 
higher and inhibition of DNA synthesis and virus 
replication were greater (data not shown). Data 
obtained at the last time period (12 hr) are presented 
as dose-response curves in Fig. 3. Increasing the 
concentration of ara-A in culture media resulted in 
higher intracellular levels of aATP and corre- 
spondingly greater inhibition of DNA synthesis and 
virus replication. 
The retention of aATP in uninfected and HSV-1- 
infected cells was compared following the removal of 
ara-A from the culture medium. In four experiments, 
removal of 10 #M ara-A from uninfected cells after 
a 6-hr incubation resulted in a decline of aATP with 
a half-life of 3.2 + 0.14 hr (mean --- S.D. of half-lives 
determined in the separate experiments) (Fig. 4). In 
contrast, in three separate experiments with HSV-1- 
infected cells, removal of 10 uM ara-A at 3 or 6 hr 
caused a decline in aATP levels with a half-life of 
9.3 - 0.63 hr (Fig. 4). The difference between the 
two half-lives is highly significant (P < 0.0001). 
These values compare to aATP half-lives of 1.7 or 
13-15 hr, respectively, in uninfected CHO cells or 
human lymphoblastoid cells observed by Plunkett 
and coworkers [35, 36]. 
Removal of ara-A after a 3-hr exposure to drug 
reduced but did not eliminate antiviral activity. 
Figure 5 illustrates that the presence of 10 ~tM ara- 
A for 3 hr resulted in an approximate 50% decline 
in virus titer compared to a >95% reduction in titer 
in cells exposed to drug for the entire incubation 
period. The 9-hr half-life of aATP in infected cells 
may explain why only a 3-hr exposure to drug 
resulted in a significant reduction in virus titer. 
The relationships between inhibition of DNA syn- 
thesis and intracellular aATP levels were examined 
in more detail by linear regression analysis. Data 
from five separate experiments were used to con- 
struct lines of best fit as functions of intraceUular 
aATP concentrations for inhibition of DNA syn- 
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Fig. 6. Correlation of intracellular aATP levels with inhibition of DNA synthesis. Intracellular con- 
centrations of aATP were compared to inhibition data by linearly regressing probit values of percent of 
control of DNA synthesis against log aATP concentrations. Data were obtained in five separate 
experiments (including those presented in Fig. 2--4) in which paired observations were made on aATP 
concentrations and DNA synthesis. Key: inhibition of DNA synthesis in uninfected (C)-- - -O) or HSV- 
1-infected KB cells (I~-----Q). 
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synthesis in HSV-l-infected cells. Figure 6 illustrates 
that the data points defined straight lines in classical 
dose-response relationships, i.e. higher intracellular 
concentrations of aATP were associated with greater 
inhibition of DNA synthesis (coefficients of cor- 
relation were -0 .89 and -0.87 for mock-infected 
and HSV-l-infected cells respectively). Tests for 
coincidence of the lines showed no difference 
between the two dose-response lines (equality of 
slopes, P = 0.32; equality of regressions, P = 0.13). 
ICs0 concentrations (and corresponding 95% con- 
fidence intervals) were calculated from the regression 
data and also showed no significant difference. The 
values were 1.8 (0.9 to 3.0) and 2.0 (1.1 to 3.2) 
pmoles aATP/106 cells, respectively, for inhibition 
of DNA synthesis in mock-infected cells and in HSV- 
1-infected cells. Assuming no drug-induced cell vol- 
ume increase at these low drug concentrations, the 
ICs0 concentrations correspond to intracellular aATP 
levels of 0.6 to 0.7/AVI. 
DISCUSSION 
Ara-A was metabolized to ara-H plus adenine 
nucleotides in both uninfected and HSV-l-infected 
KB cells. Because the same amount of ara-H was 
formed in both mock- and HSV-infected cells, we 
obtained no evidence for the induction of a viral 
adenosine deaminase. In the presence of coformycin, 
only adenine nucleotides were found in both cell 
types. When contaminating [3H]adenine was reduced 
to <10% of the label in [3H]ara-A preparations, 
ara-A was anabolized almost exclusively to adenine 
arabinosyl nucleotides. A small amount of labeled 
ribosyl nucleotides (primarily [3H]ATP) also were 
detected, suggesting that the remaining [3H]adenine 
was salvaged efficiently by adenine phosphoribosyl- 
transferase. Alternatively, ara-A could have been 
converted to ribosyl derivatives via the action of a 
purine nucleoside phosphorylase and reutilization 
of the purine base. Older observations that ATP 
formed from ara-A and subsequently was incorpor- 
ated into RNA [20,37] were attributed to the 
reutilization of labeled adenine arising from the 
phosphorolysis of ara-A [38]. 
We detected no radioactivity associated with hypo- 
xanthine arabinosylnucleotides (aHMP, aHDP or 
aHTP) whether coformycin was present or not. 
Although neither aHDP nor aHTP were available as 
reference compounds, the TLC system used for the 
present study would have detected these nucleotides. 
This observation is in contrast to that of Chang and 
Glazko [39] who found aHMP in human erythrocytes 
incubated with ara-A in the absence of an adenosine 
deaminase inhibitor. It also contrasts with the obser- 
vation of Miiller et al. [40] that intracellular metab- 
olites of ara-A consisted of 13% aHTP and 6% 
aHMP plus aHDP following incubation of L5178Y 
cells with 1.5 pM ara-A. 
aATP accumulated to the same extent in both 
uninfected and HSV-l-infected cells for 12 hr when 
incubated with concentrations of ara-A as high as 
50 pM; under these conditions the concentration of 
aATP was 130pmoles/106 cells, approximately 
40 pM. Plunkett et al. [36] reported that, within 3 hr, 
maximal levels of aATP (200-250 pmoles/106 cells) 
were achieved when CCRF-CEM cells were incu- 
bated with 100 #M ara-A. These data suggest that 
cells may not concentrate ara-A nucleotides above 
the concentration of the nucleoside in the medium 
and that aATP pools may be saturable. 
We have demonstrated previously that ara-A sel- 
ectivity inhibits viral DNA synthesis and virion rep- 
lication in KB cells [5, 7, 8]. For example, 3-5 #M 
ara-A was required to inhibit total DNA synthesis in 
uninfected and HSV-l-infected cells by 50% whereas 
0.9/~M inhibited viral DNA synthesis by 50% [8]. 
The present investigation showed that time- and 
dose-dependent formation of aATP correlated with 
inhibition of total DNA synthesis in both virus- 
infected and uninfected cells and with reduction of 
virus titers in infected cells. Fifty percent inhibition 
of total DNA synthesis was observed when the intra- 
cellular concentration of aATP was approximately 
2pmoles/106 cells, or approximately 0.7pM. By 
extrapolating to our previous studies in HSV-1- 
infected cells [8], we would expect a 3- to 5-fold 
lower concentration of aATP, roughly 0.2/zM, to 
inhibit viral (only) DNA synthesis in KB cells by 
50%. This value is remarkably consistent with Ki 
concentrations of 0.14 and 0.33 #M aATP for inhi- 
bition of isolated HSV-1 DNA polymerase reported 
by MOiler et al. [41] and by Ostrander and Cheng 
[14] respectively. The Its0 concentrations of 1.8 and 
2.0 pmoles aATP/10 6 cells (Fig. 6) also are consistent 
with the ICs0 value of 3 pmoles aATP/106 cells found 
by Plunkett et al. [36] for inhibition of thymidine 
incorporation in uninfected human lymphoblastoid 
cells. 
In addition to the known preferential inhibition of 
HSV DNA polymerase and ribonucleotide reductase 
by aATP, the current work has illuminated another 
possible mechanism which may contribute to anti- 
viral specificity. Although the observed, net rate 
and extent of aATP accumulation were the same 
in uninfected and HSV-l-infected cells, the rate of 
aATP disappearance following drug removal from 
culture medium was three times more rapid in unin- 
fected cells. (By implication, the actual rate of aATP 
synthesis also must have been more rapid in unin- 
fected cells.) Like the preferential phosphorylation 
of other antiviral nucleosides in HSV-infected cells 
[11, 24, 25], the preferential degradation of aATP in 
uninfected cells could play a significant role in anti- 
viral specificity. 
This "reverse" type of specificity may not be 
important in vitro where aATP degradation is more 
than offset by synthesis from a virtually constant 
pool of ara-A in culture medium. In experimental 
animals and humans, however, where levels of ara- 
A oscillate with dosing schedule, a more prolonged 
aATP half-life in infected cells would increase the 
crucial time during which sufficient aATP would be 
present to block DNA synthesis and virion produc- 
tion. In uninfected cells, the shorter half-life would 
be critical in reducing cytotoxic effects of the drug 
because a short period of unbalanced growth may be 
reversible. It already has been established that both 
the concentration of aATP and the duration of its 
exposure are critical determinants for the cyto- 
toxicity of ara-A in uninfected cells [42]. Thus, a 
differential kinetic effect between uninfected and 
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HSV-infected cells would give rise to greater  inhibi- 
tion in HSV-infected cells. Combined  with pref- 
erential inhibition of viral enzymes by aATP,  inhibi- 
tion of virion product ion at non-toxic drug levels 
should follow. Therefore ,  scheduling of ara-A rela- 
tive to the initiation of virion replication may be 
an important  factor in achieving selectivity against 
infections in vivo.  
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